NCT07780539

Not Yet Recruiting

Real-World Study of the Safety and Efficacy of Surufatinib i...

Yefeng Source

Compare

Other study identifiers

Sponsor study identifier

HMPL-012-RWS-BASKET101

Study Type

observational

Estimated enrollment

60

Locations

1 country

Sites

1

Timeline

Study Start

September 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

September 1, 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Study Completion

August 31, 2031

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Brief Summary

Prior clinical trials have demonstrated promising efficacy and manageable safety of surufatinib in neuroendocrine tumors (NETs). This real-world study aims to evaluate the clinical efficacy and safety of surufatinib in patients with NETs, providing additional real-world evidence to support clinical application, guide novel therapeutic strategies, and ultimately improve patient outcomes.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: not yet recruiting
Estimated enrollment: 60 participants
Study completion date: August 31, 2031
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
August 19, 2026
Actual (reported)
First Posted
August 21, 2026
Actual (reported)
Study Start
September 1, 2026
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
September 1, 2028
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
August 31, 2031
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated: August 21, 2026
Status Verified: August 2026
Last Update Submitted: August 19, 2026

Conditions

Neuroendocrine (NE) Tumors

Outcome Measures

Primary Outcomes (1)

Progression-free survival (PFS)
the time from the date of first study treatment to the date of first documented tumor progression (assessed according to RECIST version 1.1) or death due to any cause, whichever occurs first.
approximately up to 24 months

Secondary Outcomes (1)

Objective response rate (ORR)
approximately up to 24 months

Study Arms (1)

surufatinib

Surufatinib therapy

Drug: Surufatinib Administration

Interventions

Surufatinib AdministrationDrug

Surufatinib as monotherapy or combination therapy, at the discretion of the investigator based on the patient's overall condition.

surufatinib

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Advanced neuroendocrine tumor

You may qualify if:

Patients with pathologically or cytologically confirmed neuroendocrine tumors;

Sponsors & Collaborators

Yefeng
Otherlead

Study Sites (1)

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

Feng YeCONTACT+86-592-2137569 yefengdoctor@sina.com

MeSH Terms

Conditions

Neoplasms

Study Officials

Feng Ye
The First Affiliated Hospital of Xiamen University
PRINCIPAL INVESTIGATOR

Central Study Contacts

Feng Ye

CONTACT

+86-592-2137569 yefengdoctor@sina.com

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: The First Affiliated Hospital of Xiamen University

Study Record Dates

First Submitted

August 19, 2026

First Posted

August 21, 2026

Study Start

September 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

NCT02588170

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Phase 3Completed

NCT04814732

Expanded Access Program of Surufatinib

Unknown

NCT05989425

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Phase 2Unknown

NCT05171439

Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples

Phase 2Unknown

NCT05013515

Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas

Not ApplicableUnknown

NCT05282433

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

Phase 2Unknown

At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;

Life expectancy ≥ 12 weeks;

Adequate organ and bone marrow function

You may not qualify if:

Participation in other drug clinical trials with investigational drug treatment within the past 4 weeks;
History of other malignancies within the past 5 years, except for curatively resected basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ;
Patients with contraindications to surufatinib (e.g., active bleeding, ulcer, intestinal perforation, intestinal obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, within 30 days after major surgery, severe hepatic or renal impairment, etc.);
Presence of any disease or condition that affects drug absorption, or inability to take surufatinib orally;
Any condition deemed by the investigator as unsuitable for study drug treatment.

Contact the study team to confirm eligibility.

September 1, 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Study Completion

August 31, 2031

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated

August 21, 2026

Record last verified: 2026-08

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT07780539
Data provider: ClinicalTrials.gov
Source updated: 2026-08-21
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:29:53 UTC

Locations

CN(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

surufatinib

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations